C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.950
+0.105 (2.73%)
At close: Dec 20, 2024, 4:00 PM
3.970
+0.020 (0.51%)
After-hours: Dec 20, 2024, 7:31 PM EST
C4 Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for C4 Therapeutics stock have an average target of 10.67, with a low estimate of 4.00 and a high estimate of 20. The average target predicts an increase of 170.13% from the current stock price of 3.95.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CCCC stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 2 | 1 | 1 | 1 | 1 | 2 |
| Hold | 4 | 4 | 4 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $8 → $12 | Hold → Buy | Upgrades | $8 → $12 | +203.80% | Dec 19, 2024 |
| Stephens & Co. | Stephens & Co. | Hold Initiates $4 | Hold | Initiates | $4 | +1.27% | Nov 18, 2024 |
| BMO Capital | BMO Capital | Buy Reiterates $20 | Buy | Reiterates | $20 | +406.33% | Aug 6, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $7 → $8 | Hold | Maintains | $7 → $8 | +102.53% | May 9, 2024 |
| Stifel | Stifel | Strong Buy Maintains $13 → $14 | Strong Buy | Maintains | $13 → $14 | +254.43% | May 9, 2024 |
Financial Forecast
Revenue This Year
36.49M
from 20.76M
Increased by 75.79%
Revenue Next Year
16.95M
from 36.49M
Decreased by -53.55%
EPS This Year
-1.55
from -2.67
EPS Next Year
-1.77
from -1.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 42.4M | 31.5M | 38.6M | |||
| Avg | 36.5M | 16.9M | 18.1M | |||
| Low | 29.4M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 104.4% | -13.7% | 128.0% | |||
| Avg | 75.8% | -53.5% | 6.7% | |||
| Low | 41.6% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.51 | -1.49 | -1.40 | |||
| Avg | -1.55 | -1.77 | -1.73 | |||
| Low | -1.58 | -1.86 | -2.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.